Clinical trials: Proliferative Diabetic Retinopathy (PDR)
Proliferative Diabetic Retinopathy
Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative IAI at…
- Trial name
- LASERLESS (NCT02976012)
- Testing
- Aflibercept, Endolaserless Vitrectomy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR
In this randomized 3-armed clinical trial, 105 eyes with PDR will be included and divided randomly into 3 groups: IVB group (35 eyes) that receive 4 monthly IVB injections and then rescue IVB, PRP group (35 eyes) that undergo…
- Trial name
- NCT04800679
- Testing
- receive 4 monthly IVB injections and then rescue IVB, PRP group, IVB injections and a modified laser
- Where
- Iran
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Proliferative Diabetic Retinopathy (PDR)
Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
The present study is intended to evaluate the safety and tolerability of topical OC-10X Ophthalmic Suspension in healthy human subjects. OcuCure Therapeutics, Inc.
- Trial name
- NCT01869933
- Testing
- OC-10X
- Where
- Bangladesh
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OcuCure Therapeutics, Inc.